Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin in Infective Endocarditis
NCT07699211Phase 3Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of dalbavancin in infective endocarditis (IE). Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dalbavancin
03
Conditions
infective endocarditis (IE)
Beyond the preview
Go deeper on NCT07699211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699211.